The United States will announce the list of selected participants for the third round of drug price negotiations in February next year.

The Centers for Medicare and Medicaid Services (CMS) in the United States plans to list up to 15 drugs selected for the third round of price negotiations by February 1, 2026, and seek public input. CMS released draft guidance on the plan later Monday and stated that, in addition to drugs covered by Part D of the federal Medicare program, this round of negotiations will also include drugs paid for under Part B for the first time, with anticipated adjustments to drug prices by 2028. In 2023, CMS announced the selection of 10 drugs covered by Part D for the first round of price negotiations, which concluded in August 2024. The initial list included blockbuster therapies from companies such as Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly, AbbVie, Johnson & Johnson, Bayer, and Astrazeneca PLC Sponsored ADR. In January of this year, the agency announced an additional 15 drugs covered by Part D selected for the second round of price negotiations. Popular weight loss drug Wegovy from Novo Nordisk A/S Sponsored ADR Class B was among them, as well as blockbuster drugs from GlaxoSmithKline plc Sponsored ADR, Ironwood Pharmaceuticals, Inc. Class A, Teva Pharmaceutical Industries Limited Sponsored ADR, and Theravance Biopharma. The 45-day public comment period will continue until June 26, 2025.